Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + Oxaliplatin
Phase 2RecruitingDevelopment Stage
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Dec 13, 2024 → Oct 1, 2030
About Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + Oxaliplatin
Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + Oxaliplatin is a phase 2 stage product being developed by AbbVie for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06628310. Target conditions include Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06628310 | Phase 2 | Recruiting |
Competing Products
20 competing products in Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma